Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Extract

This editorial refers to ‘Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes’†, by S. Kodali et al., on page 449.

Transcatheter aortic valve implantation (TAVI) has become the treatment of choice for inoperable patients with severe aortic stenosis and is a valuable therapeutic option for patients at high risk.1,2 Recent data suggest that TAVI can also be adopted in intermediate risk patients with competitive results when compared with surgery.3

For further expansion of indications, TAVI should, however, be demonstrated to be safe and effective in the longer term, and reduce the rate of complications. Paravalvular leak (PVL) after TAVI is a frequent problem and is considered the Achille's heel of TAVI. A recent meta-analysis including 12 926 TAVI patients reported a pooled estimate incidence of moderate or severe PVL of 11.7%.4 Residual moderate/severe PVL has a relevant negative prognostic impact and has been associated with an increased risk of all-cause mortality.4 More recently, it has been suggested that mild PVR may also be a relevant predictor of mortality, but this association remains controversial.4

Issue Section:
Editorials
You do not currently have access to this article.
Download all slides